8th Annual Digital Biomarkers in Clinical Trials Summit

8th Annual Digital Biomarkers in Clinical Trials Summit is organized by PanAgora Pharma, Roche and will be held on Jun 25, 2025 at Roche Tower (Building 1), Basel, Basel-Stadt, Switzerland.

Description:
The Digital Biomarkers in Clinical Trials Summit is the first and only global forum of its kind to focus on ways for pharma clinical trials to take advantage of new opportunities to collect better data and improve the patient experience; as well as how these new digital health tools (DHT) supplement existing biomarker strategies.

Join 40+ speakers and advisors, 350+ senior-level pharma, clinical trials, technology and digital health executives in Basel to learn, network, develop and improve the way pharma clinical trials utilize mobile-enabled, wearables, and decentralized clinical trial capabilities to improve existing biomarker strategies, improve patient experience and collect better data.

Global experts converge at the forefront of wearable sensor technology, data management, analytics, connected device, decentralized clinical trials & biomarkers strategies in clinical research. If you’re involved with R&D, sales & marketing, information technology, data management, patient recruitment, retention, adherence, artificial intelligence, digital health, digital biomarkers, decentralized trials, quantitative or translational medicine - this is the place to be.

Latest Developments in Digital Biomarkers:
1. Digital Biomarkers in Obesity / Cardiovascular

• Beyond the more established field of measuring activity levels and other symptoms with DHTs, what additional measurement approaches are being explored within obesity and cardiovascular?

2. Digital Biomarkers in Neuroscience

• Showcasing the biggest impacts Digital Biomarkers have had in Neuroscience clinical development today

3. Digital Biomarkers in Immunology

• What Digital Biomarker use cases are actively being explored in immunology and immunotherapy? What are the major advances in monitoring safety?

4. Measuring what Matters to Patients and Regulatory Path Forward

• Are there differences between what can technically be measured and what patients would like us to measure?
• What can be done to accelerate Digital Endpoint development?
• What role can partnerships between patients, Digital Health Technology (DHT) vendors, clinical trial sites & biopharmaceutical companies play?
• What are the challenges within the current regulatory landscape, and how can these be addressed?